Research Progress and Application of Bispecific Nanobody

doi:10.13523/j.cb.2011027

China Biotechnology

2021, Vol. 41

Issue (2/3): 78-88 DOI: 10.13523/j.cb.2011027

Research Progress and Application of Bispecific Nanobody

YUAN Bo^1,²,WANG Jie-wen^1,²,KANG Guang-bo^1,²,HUANG He^1,^2,^***(

)

1 Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
2 Key Laboratory of Systems Bioengineering of Ministry of Education, Tianjin University, Tianjin 300072, China

Download:

HTML

PDF(7586KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

This article reviews the application and advances of bispecific nanobodies from the research progress of nanobodies and studies of bispecific nanobodies in treating infectious diseases, cancer, and immune system diseases. Moreover, it highlights the research hotspots and potential research areas at this current stage. For in-depth analysis, the differences between nanobodies and full-length monoclonal antibodies are compared and the unique advantages of bispecific nanobodies are demonstrated. The research progress of nanobodies has been summarized, while emphasizing the research hot spots of neutralizing nanobodies of the COVID-19, CAR-T cell therapy, and immune checkpoint therapy antibodies. In conclusion, a prospect analysis of the application prospects of bispecific nanobodies is carried out. It is pointed out that bispecific nanobodies are able to overcome the shortcomings of full-length antibody and become a form of the antibody with great druggability.

Key words： Nanobody Bispecific antibody Infectious diseases Tumor therapy Immune diseases

Received: 16 November 2020 Published: 08 April 2021

ZTFLH:

Q51

Corresponding Authors: He HUANG E-mail: huang@tju.edu.cn

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Bo YUAN
	Jie-wen WANG
	Guang-bo KANG
	He HUANG

Cite this article:

YUAN Bo,WANG Jie-wen,KANG Guang-bo,HUANG He. Research Progress and Application of Bispecific Nanobody. China Biotechnology, 2021, 41(2/3): 78-88.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2011027 OR https://manu60.magtech.com.cn/biotech/Y2021/V41/I2/3/78

Fig.1 The different types of bispecific antibodies (a) The conventional full-length monoclonal antibody (b) The camelid heavy chain antibody (c) Single-chain fragment variable(scFv) antibody (d) Nanobody^? or VHH (e) Bispecific nanobody (f)Bispecific nanobody KN046 (g) Bispecific T cell engagers

Fig.2 The application of bisspecific nanobodies in different treatment fields

Table1 Anti-infectious diseases bispecific nanobodies

Table 2 Anti-tumor bispecific nanobodies

Table 3 Immune disease bispecific nanobodies


[1]	Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature, 1993,363(6428):446-448.

[2]	Cheng X, Wang J W, Kang G B, et al. Homology modeling-based in silico affinity maturation improves the affinity of a nanobody. International Journal of Molecular Sciences, 2019,20(17):E4187.

[3]	Hu M, Kang G B, Cheng X, et al. In vitro affinity maturation to improve the efficacy of a hypoxia-inducible factor 1α single-domain intrabody. Biochemical And Biophysical Research Communications, 2020,529(4):936-942.

[4]	Yang E Y, Shah K. Nanobodies: next generation of cancer diagnostics and therapeutics. Frontiers in Oncology, 2020,10:1182. pmid: 32793488

[5]	Wang J, Mukhtar H, Ma L, et al. VHH antibodies: reagents for mycotoxin detection in food products. Sensors(Basel Switzerland), 2018,18(2):E485.

[6]	Liu Y K, Huang H. Expression of single-domain antibody in different systems. Applied Microbiology and Biotechnology, 2018,102(2):539-551.

[7]	Li R W, Kang G B, Hu M, et al. Ribosome display: a potent display technology used for selecting and evolving specific binders with desired properties. Molecular Biotechnology, 2019,61(1):60-71.

[8]	Peyvandi F, Scully M, Kremer Hovinga J A, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Heamostasis, 2017,15(7):1448-1452.

[9]	Conrath K, Vanhollebeke B, Pays E, et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nature Medicine, 2006,12(5):580-584.

[10]	Ren J, Zhang C, Ji F L, et al. Characterization and comparison of two peptide-tag specific nanobodies for immunoaffinity chromatography. Journal of Chromatography A, 2020,1624:461227.

[11]	Kontermann R E, Brinkmann U. Bispecific antibodies. Drug Discovery Today, 2015,20(7):838-847. doi: 10.1016/j.drudis.2015.02.008 pmid: 25728220

[12]	于蕊, 陈昭烈. 新型双特异性单链抗体BiTEs及其在肿瘤治疗中的应用前景. 中国生物工程杂志, 2004,24(4):2-6.

[12]	Yu R, Chen Z L. New type bispecific single-chain antibodies BiTEs and its prospect in cancer clinical trials. China Biotechnology, 2004,24(4):2-6.

[13]	Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Frontiers in Immunology, 2017,8:1603.

[14]	Coppieters K, Dreier T, Silence K, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis and Rheumatism, 2006,54(6):1856-1866. doi: 10.1002/art.21827 pmid: 16736523

[15]	Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. Journal of Controlled Release, 2012,161(2):429-445.

[16]	van Roy M, Ververken C, Beirnaert E, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody? ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Research & Therapy, 2015,17:135.

[17]	Hmila I, Saerens D, Abderrazek R B, et al. A bispecific nanobody to provide full protection against lethal scorpion envenoming. The FASEB Journal, 2010,24(9):3479-3489. doi: 10.1096/fj.09-148213 pmid: 20410443

[18]	Yang Z Y, Schmidt D, Liu W L, et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. The Journal of Infectious Diseases, 2014,210(6):964-972. pmid: 24683195

[19]	Taylor P, Rossotti M A, González-Techera A, et al. Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain. mAbs, 2015,7(5):820-828. pmid: 26192995

[20]	Herrera C, Tremblay J M, Shoemaker C B, et al. Mechanisms of ricin toxin neutralization revealed through engineered homodimeric and heterodimeric camelid antibodies. Journal of Biological Chemistry, 2015,290(46):27880-27889.

[21]	Vrentas C E, Moayeri M, Keefer A B, et al. A diverse set of single-domain antibodies (VHHs) against the anthrax toxin lethal and edema factors provides a basis for construction of a bispecific agent that protects against anthrax infection. The Journal of Biological Chemistry, 2016,291(41):21596-21606.

[22]	Moayeri M, Tremblay J M, Debatis M, et al. Adenoviral expression of a bispecific VHH-based neutralizing agent that targets protective antigen provides prophylactic protection from Anthrax in mice. Clinical and Vaccine Immunology, 2016,23(3):213-218.

[23]	Mars A, Bouhaouala-Zahar B, Raouafi N. Ultrasensitive sensing of Androctonus australis hector scorpion venom toxins in biological fluids using an electrochemical graphene quantum dots/nanobody-based platform. Talanta, 2018,190:182-187. doi: 10.1016/j.talanta.2018.07.087 pmid: 30172496

[24]	Sheikhi A, Hojjat-farsangi M. An immunotherapeutic method for COVID-19 patients?: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein. Human Vaccines & Immunotherapeutics, 2021: 17(1):92-97. pmid: 32663051

[25]	Huo J D, le Bas A, Ruza R R, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nature Structural & Molecular Biology, 2020,27(9):846-854.

[26]	Cheng H W, Yang L, Cai Z Z, et al. Development of haemagglutination assay for titration of porcine circovirus type 2. Analytical Biochemistry, 2020,598:113706. doi: 10.1016/j.ab.2020.113706 pmid: 32275892

[27]	Chen Z C, Moayeri M, Purcell R. Monoclonal antibody therapies against Anthrax. Toxins, 2011,3(8):1004-1019.

[28]	沈玉栋, 张咏仪, 徐振林, 等. 一种百草枯半抗原PH-A、人工抗原、抗体及其制备方法和应用:中国,CN111454171A. 2020-03-26[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN111454171A&v=5W8Nfq0MU44GN8hfMungTesma9snz5lz4DdkffpZGdyLeswkG7SD58%25mmd2Fz2s5ZvTFu

[28]	Shen Y D, Zhang Y Y, Xu Z L,. et al. Paraquat hapten PH-A, artificial antigen, antibody and preparation methods and applications:Chinese, CN111454171A. 2020-03-26[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN111454171A&v=5W8Nfq0MU44GN8hfMungTesma9snz5lz4DdkffpZGdyLeswkG7SD58%25mmd2Fz2s5ZvTFu

[29]	Wang F, Li Z F, Yang Y Y, et al. Chemiluminescent enzyme immunoassay and bioluminescent enzyme immunoassay for tenuazonic acid mycotoxin by exploitation of nanobody and nanobody-nanoluciferase fusion. Analytical Chemistry, 2020,92(17):11935-11942.

[30]	Xiang Y, Nambulli S, Xiao Z, et al. Versatile, multivalent nanobody cocktails efficiently neutralize SARS-CoV-2. bioRxiv: the preprint server for biology, 2020,370(6523):1479-1484.

[31]	Raybould M I J, Kovaltsuk A, Marks C, et al. CoV-AbDab: the coronavirus antibody database. Bioinformatics, 2020, 2-3.DOI (10.1093): bioinformatics.

[32]	Vosjan M J W D, Vercammen J, Kolkman J A, et al. Nanobodies targeting the hepatocyte growth factor?: potential new drugs for molecular cancer therapy. Molecular Cancer Therapeutics, 2012,11(4):1017-1025. doi: 10.1158/1535-7163.MCT-11-0891 pmid: 22319202

[33]	Ding L, Tian C P, Feng S, et al. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy. Theranostics, 2015,5(4):378-398.

[34]	Alvarez-Cienfuegos A, Nu?ez-Prado N, Compte M, et al. Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains. Scientific Reports, 2016,6:28643. pmid: 27345490

[35]	Shibuya Y, Haga N, Asano R, et al. Generation of camelid VHH bispecific constructs via in-cell intein-mediated protein trans-splicing. Protein Engineering Design and Selection, 2017,30(1):15-21.

[36]	李洪利, 李福胜, 林兆新, 等. 一种CD3ε×CD19双特异性纳米抗体及其制备方法:中国,CN106939048A. 2017-07-11[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2017&filename=CN106939048A&v=sfdvmO1KUQihZoeq6wTRZHAEMhfJgkiRN%25mmd2BbhICl2wSpS4a81IRLPAlbB5Z3vBnMr.

[36]	Li H L, Li F S, Lin Z X, et al. CD3epsilon×CD19 bispecific nanometer antibody and preparation method:Chinese CN106939048A. 2017-07-11[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2017&filename=CN106939048A&v=sfdvmO1KUQihZoeq6wTRZHAEMhfJgkiRN%25mmd2BbhICl2wSpS4a81IRLPAlbB5Z3vBnMr.

[37]	de Bruin R C G, Veluchamy J P, Lougheed S M, et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. OncoImmunology, 2018,7(1):e1375641.

[38]	Zhu Y N, Bassoff N, Reinshagen C, et al. Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Scientific Reports, 2017,7(1):2602. doi: 10.1038/s41598-017-02483-9 pmid: 28572590

[39]	Nikkhoi S K, Rahbarizadeh F, Ranjbar S, et al. Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targeting. Molecular Immunology, 2018,96:98-109.

[40]	Li Y M, Zhou C H, Li J, et al. Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. PLoS One, 2018,13(1):e0190124.

[41]	de Munter S, Ingels J, Goetgeluk G, et al. Nanobody based dual specific CARs. International Journal of Molecular Sciences, 2018,19(2):403.

[42]	Pan H T, Liu J Y, Deng W T, et al. Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy. International Journal of Nanomedicine. 2018,13:3189-3201.

[43]	Zhao Y N, Li Y M, Wu X Q, et al. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies. Cancer Biology & Therapy, 2020,21(1):72-80.

[44]	He X, Feng Z J, Ma J, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood, 2020,135(10):713-723.

[45]	Pedersen D V, R?sner T, Hansen A G, et al. Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement. Molecular Immunology. 2020,124:200-210. pmid: 32599335

[46]	李黄金, 赵林, 温碧燕. 一种靶向EGFR二聚体界面的人源化双特异性纳米抗体: 中国,CN110894239A. 2020-03-20[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN110894239A&v=DlYicxrxGrtlMNGbM2MfzB0%25mmd2F4zK80ifckpSxcPZ1kZCatCy4KK7jCJA7WXokkk5K.

[46]	Li H J, Zhao L, Wen B Y. Humanized bispecific nano antibody targeting EGFR(epidermal growth factor receptor) dimer interface:Chinese CN110894239A. 2020-03-20[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN110894239A&v=DlYicxrxGrtlMNGbM2MfzB0%25mmd2F4zK80ifckpSxcPZ1kZCatCy4KK7jCJA7WXokkk5K.

[47]	梁爱斌, 李萍. CAR-T细胞治疗淋巴瘤的研究进展. 临床血液学杂志, 2020,33(5):599-603.

[47]	Liang A B, Li P. Research progress of CAR-T therapy in the treatment of lymphoma. Journal of Clinical Hematology, 2020,33(5):599-603.

[48]	Zajc C U, Salzer B, Taft J M, et al. Driving CARs with alternative navigation tools - the potential of engineered binding scaffolds. The FEBS Journal, 2020: feb,15523.

[49]	Rahbarizadeh F, Ahmadvand D, Moghimi S M. CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs. Advanced Drug Delivery Reviews, 2019,141:41-46. doi: 10.1016/j.addr.2019.04.006 pmid: 31004624

[50]	王振, 李静. 一种靶向CD19的新型嵌合抗原受体(CAR)及其应用: 中国,CN109721659A. 2019-05-07[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2019&filename=CN109721659A&v=mfRgSc1RPW5f%25mmd2FDkaTH2BlT%25mmd2FDCnoHiyAtjypz2a3pyibO9mCIb8r0iK6nFRwm%25mmd2F6rj.

[50]	Wang Z, Li J. Novel chimeric antigen receptor (CAR) targeting CD19 and applications:Chinese, CN109721659A. 2019-05-07[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2019&filename=CN109721659A&v=mfRgSc1RPW5f%25mmd2FDkaTH2BlT%25mmd2FDCnoHiyAtjypz2a3pyibO9mCIb8r0iK6nFRwm%25mmd2F6rj.

[51]	Tseng D, Volkmer J P, Willingham S B, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proceedings of the National Academy of Sciences of the United States of America, 2013,110(27):11103-11108.

[52]	Ma L L, Zhu M, Gai J W, et al. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential. Journal of Nanobiotechnology, 2020,18(1):1-12. doi: 10.1186/s12951-019-0560-5 pmid: 31898555

[53]	赵振东, 张重阳, 吴维海. 一种靶向于CD22分子的嵌合抗原受体:中国,CN111518217A. 2020-08-11[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN111518217A&v=IY2z3dn10aQ%25mmd2BsG80J5fCLlmVYMax9gRMaYOw9Gx7sw%25mmd2FN7no7RdaoLlxPYApbCUG8.

[53]	Zhao Z D, Zhang Z Y, Wu W H. The chimeric antigen receptor (CAR) targeting CD22 and applications:Chinese, CN111518217A. 2020-08-11[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN111518217A&v=IY2z3dn10aQ%25mmd2BsG80J5fCLlmVYMax9gRMaYOw9Gx7sw%25mmd2FN7no7RdaoLlxPYApbCUG8.

[54]	Chen L P, Han X. Anti-PD-1 / PD-L1 therapy of human cancer: past,present,and future. The Journal of Clinical Investigation, 2015,125(9):3384-3391. doi: 10.1172/JCI80011 pmid: 26325035

[55]	Wolchok J D, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet Oncology, 2010,11(2):155-164. doi: 10.1016/S1470-2045(09)70334-1 pmid: 20004617

[56]	Reichert J M. Antibodies to watch in 2014. mAbs, 2014,6(4):799-802. doi: 10.4161/mabs.29282 pmid: 24846335

[57]	Zuazo M, Gato-Ca?as M, Llorente N, et al. Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy. Annals of Translational Medicine, 2017,5(19):385. doi: 10.21037/atm.2017.06.11 pmid: 29114543

[58]	Zou W P, Chen L P. Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 2008,8(6):467-477. doi: 10.1038/nri2326 pmid: 18500231

[59]	万亚坤, 朱敏, 盖军伟, 等. 抗PD-L1/4-1BB双特异性抗体及其用途:中国,CN110627906A. 2019-12-31[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN110627906A&v=T6F71Of58Ttb9ZgZhv0FsoWqz%25mmd2F2dk4ZZGIuFH5h0cdffN3QrOBy95aq9kpM5BNeS.

[59]	Wan Y K, Zhu M, Gai J W, et al. Anti-PD-L1/4-1BB bispecific antibody and use:Chinese, CN110627906A. 2019-12-31[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN110627906A&v=T6F71Of58Ttb9ZgZhv0FsoWqz%25mmd2F2dk4ZZGIuFH5h0cdffN3QrOBy95aq9kpM5BNeS.

[60]	张飞. PD-L1抗体和CTLA-4抗体介导肿瘤免疫治疗的结构生物学机制研究. 上海:上海交通大学, 2018.

[60]	Zhang F. Structural mechanisms of PD-L1 and CTLA-4 antibodies mediated tumor immunotherapy. Shanghai:Shanghai Jiaotong University, 2018.

[61]	Biologics W, Co S, Biologics W, et al. New programmed death 1 binding molecule comprising at least one immunoglobulin single variable domain: China, WO2017196847-A1. 2017-11-16[2020-10-14]. http://apps.webofknowledge.com/full_record.do?colName=DIIDW&recordID=2017783473&log_event=no&search_mode=GeneralSearch&excludeEventConfig=ExcludeIfFromFullRecPage&qid=1&log_event=yes&product=UA&SID=8FwlP5CmRf2oG2FpDr2&viewType=fullRecord&doc=3&page=1.

[62]	Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer, 2004,4(1):11-22. doi: 10.1038/nrc1252 pmid: 14708024

[63]	Dougan M, Ingram J R, Jeong H J, et al. Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1-specific VHHs. Cancer Immunology Research, 2018,6(4):389-401. pmid: 29459478

[64]	李可馨, 崔巍. 补体介导的肿瘤免疫逃逸及其在免疫检查点抑制剂治疗中的应用. 中华检验医学杂志, 2019,42(12):981-985.

[64]	Li K X, Cui W. Complement mediated tumor immune escape and its application in immune checkpoint inhibitors therapy. Chinese Journal of Laboratory Medicine, 2019,42(12):981-985.

[65]	李翠. 纳米抗体双特异性T细胞激动剂CD3-FAP/nanoBiTE抗肿瘤效应研究. 南宁:广西医科大学, 2018.

[65]	Li C. Anti-tumor effect of nanobody-specific bispecific T cell engager CD3-FAP/NanoBiTE. Nanning:Guangxi Medical University, 2018.

[66]	贾羽. HER-2双特异性纳米抗体的筛选及功能鉴定. 北京:北京化工大学, 2018.

[66]	Jia Y. Construction and functional identification of bispecific nanobody for HER-2. Beijing: Beijing University of Chemical Technology, 2018.

[67]	Kaushik S B, Lebwohl M G. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. Journal of the American Academy of Dermatology, 2019,80(1):27-40. doi: 10.1016/j.jaad.2018.06.057 pmid: 30017705

[68]	van Overbeke W, Verhelle A, Everaert I, et al. Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model. Molecular Therapy, 2014,22(10):1768-1778. pmid: 25023329

[69]	Steeland S, Puimège L, Vandenbroucke R E, et al. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. The Journal of Biological Chemistry, 2015,290(7):4022-4037. doi: 10.1074/jbc.M114.617787 pmid: 25538244

[70]	Verhelle A, Nair N, Everaert I, et al. AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. Human Molecular Genetics, 2017,26(7):1353-1364. doi: 10.1093/hmg/ddx056 pmid: 28334940

[71]	Infirmary L G, Green L. Safety and efficacy of multiple ascending doses of subcutaneous M1095, an anti-interleukin-17A/F bispecific nanobody, in patients with moderate-to-severe psoriasis. Journal of the American Academy of Dermatology, 2017,76(6): AB224.

[72]	Steeland S, van Ryckeghem S, Vandewalle J, et al. Simultaneous Inhibition of tumor necrosis factor receptor 1 and matrix metalloproteinase 8 completely protects against acute inflammation and sepsis. Critical Care Medicine, 2018,46(1):E67-E75. doi: 10.1097/CCM.0000000000002813 pmid: 29095202

[73]	Strokappe N M, Hock M, Rutten L, et al. Super potent bispecific llama VHH antibodies neutralize HIV via a combination of gp41 and gp120 epitopes. Antibodies, 2019,8(2):38.

[74]	Pan H C, Su Y N, Xie Y N, et al. Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects. Artificial Cells,Nanomedicine and Biotechnology, 2020,48(1):854-866.

[75]	Jossten L A, Helsen M M, van de Loo F A, et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis & Rheumatism, 1996,39(5):797-809.

[1]	LV Hui-zhong,ZHAO Chen-chen,ZHU Lian,XU Na. Progress of Using Exosome for Drug Targeted Delivery in Tumor Therapy[J]. China Biotechnology, 2021, 41(5): 79-86.

[2]	MAO Kai-yun,LI Rong,LI Dan-dan,ZHAO Ruo-chun,FAN Yue-lei,JIANG Hong-bo. Analysis of the Current Status of Global Bispecific Antibody Development[J]. China Biotechnology, 2021, 41(11): 110-118.

[3]	LIN Shi-xin,LIU Dong-chen,LEI Yun,XIONG Sheng,XIE Qiu-ling. Screening, Expression and Specificity Detection of Anti-TNF-α Nanobody[J]. China Biotechnology, 2020, 40(7): 15-21.

[4]	YANG Xiao-ying,LI Meng,ZHAO Wei,TANG Min,ZHANG Zhi-qian. Preparation and Preliminary Characterization of Anti-α2δ1/CD3 Bispecific Antibody[J]. China Biotechnology, 2020, 40(7): 9-14.

[5]	MEI Ya-xian,WANG Yue,LUO Wen-xin. Application of Nano-antibody in the Prevention, Diagnosis and Treatment of Infectious Diseases[J]. China Biotechnology, 2020, 40(10): 24-34.

[6]	LU Zhong-teng,HU Gao-wei. Identification Methods of Novel Cell Penetrating Peptides and Application in Antitumor Therapy[J]. China Biotechnology, 2019, 39(12): 50-55.

[7]	Jin-jing LI,Fei XU,Yan-wei JI,Mei SHU,Zhui TU,Jin-heng FU. Biopanning of Anti c-Myc-tag Nanobodies and Its Application for Bioimaging[J]. China Biotechnology, 2018, 38(2): 61-67.

[8]	LI Dan, HUANG He. Heterologous Expression of Nanobodies:a Recent Progress[J]. China Biotechnology, 2017, 37(8): 84-95.

[9]	YANG Yu, LIU Ya, GU Lan, ZHAO Ting-ting, REN Lu-feng. The Current Situation and the Development Trend of Automatic Nucleic Acid Molecular Diagnostic System[J]. China Biotechnology, 2017, 37(3): 115-123.

[10]	LI You-jian, ZHANG guo-qi, Gou ji-xing, CHEN xin-kai, DOU Xiao-xia, CHEN Chuang-fu, SHENG Jin-liang. Expression of Ovine Myostatin Gene and Construction and Identification of Nanobody Library Against Recombinant MSTN[J]. China Biotechnology, 2014, 34(9): 87-93.

[11]	LI Bing-juan, LI Yu-xia, LI Bei-ping, LING Yan, ZHOU Wei, LI Wei-dong, LIN Hai-long, LIANG Long, LIU Gang, ZHANG Jin-hai, CHEN Hui-peng. Construction and Evaluation of the Mutated Anthrax Toxin Proteins as Drug Deliver System for Targeting Tumor Cells[J]. China Biotechnology, 2013, 33(4): 1-8.

[12]	DU Juan- Hu-Gong-Gang- Hou-Ling-Ling. Application of IL-13Rα2-directed Toxin Fusion Protein in Tumor Therapy[J]. China Biotechnology, 2009, 29(04): 98-103.

Viewed

Full text

Abstract

Cited

Shared

Discussed